The Form 4 filing, a report of an insider's stock activity, lists Andrew D. Dickinson as chief financial officer of Gilead Sciences (GILD). The sale took place on November 16, 2026. The filing followed on November 17, 2026.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-16 |
| Date of Latest Transaction | 2026-11-16 |
| Buy/Sell | sell |
| Transaction Count | 1 |
| Shares Transacted | 3,000 |
| Price | $171.47 |
| Total Transaction Value | $514,410.00 |
| Insider | |
| Ticker Symbol | GILD |
| Company | GILEAD SCIENCES, INC. |
| Insider Name | Dickinson Andrew D |
| Insider Title | Chief Financial Officer |
| Sector - Industry | Healthcare - Drug Manufacturers - General |
| Holdings | |
| Total Shares Owned After Transaction | 158,096 |
| Position Size Change | 1.86% |
| Filing | |
| Filing Date | 2026-11-17 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
Andrew D. Dickinson sold 3,000 shares in one transaction. The transaction code is S, which identifies a sale.
What was the average price of the transaction?
The reported average price was $171.47 per share. This was the price reported for the single transaction on November 16, 2026.
How did this transaction affect the insider's holdings?
Dickinson sold 3,000 shares and reported owning 158,096 shares afterward. The sale covered 1.86% of his reported shares owned before the trade.
What's the total transaction value?
The total value was $514,410.00. That amount covers all 3,000 shares reported in the single sale.
Are there any special circumstances around this transaction?
The transaction information includes a reference to a Rule 10b5-1 trading plan. These plans set trading instructions in advance. The reference may apply to the filing as a whole, so it does not confirm that this specific sale was covered by the plan. No footnote text was available to confirm which trades the plan covered, when it was adopted, or its terms. The reference alone does not establish that the sale met the rule's legal requirements.
For research purposes only; not investment advice.